Brentuximab Vedotin (BV) in Combination With Lenalidomide (Len) and Rituximab (R) in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL): Results From the Phase 3 ECHELON-3 Study

Saved in:
Bibliographic Details
Published in:Clinical lymphoma, myeloma and leukemia myeloma and leukemia, 2024-09, Vol.24, p.S220-S220
Main Authors: Yasenchak, Christopher, Kim, Jeong-A, Hahn, Uwe, Kim, Won-Seog, Fleury, Isabelle, Laribi, Kamel, Miguel Bergua Burgues, Juan, Bouabdallah, Krimo, Forward, Nicholas, Bijou, Fontanet, MacDonald, David, Portell, Craig, Ghesquieres, Herve, Nowakowski, Grzegorz, Rustia, Evelyn, Fanale, Michelle, Jie, Fei, Bartlett, Nancy
Format: Article
Language:English
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:
ISSN:2152-2650
DOI:10.1016/S2152-2650(24)00845-0